Drug impurity profiling strategies

S. Görög, M. Babják, G. Balogh, J. Brlik, A. Csehi, F. Dravecz, M. Gazdag, P. Horváth, A. Laukó, K. Varga

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

A general scheme is set up for the estimation of the impurity profile of bulk drug substances by the complex use of chromatographic, spectroscopic and hyphenated techniques. Several examples are presented as illustrations to the scheme from the authors laboratory involving the use of chromatographic methods such as thin-layer-(TLC), gas-(GC), analytical and preparative high-performance liquid chromatography (HPLC), spectroscopic methods such as mass spectrometry (MS) and NMR spectroscopy as well as hyphenated techniques (HPLC/diode-array UV, GC/MS and HPLC/MS). In addition to summarizing earlier work, new examples are also presented: identification of an impurity (propyl 4-[diethylcarbamoyl(methoxy)]-3-methoxy phenylglyoxylate, II) in propanidid (I) and two unsaturated impurities in allylestrenol (VII) by GC/MS and HPLC/diode-array UV as well as estimation of the impurity profile of mazipredone (III) by HPLC/MS and HPLC/diode-array UV.

Original languageEnglish
Pages (from-to)1517-1526
Number of pages10
JournalTalanta
Volume44
Issue number9
DOIs
Publication statusPublished - Sep 1997

Fingerprint

Drug Contamination
High performance liquid chromatography
Mass Spectrometry
Mass spectrometry
High Pressure Liquid Chromatography
Impurities
Pharmaceutical Preparations
Diodes
Allylestrenol
Propanidid
Nuclear magnetic resonance spectroscopy
Magnetic Resonance Spectroscopy
Gases

Keywords

  • Allylestrenol
  • Impurities
  • Mazipredone
  • Propanidid

ASJC Scopus subject areas

  • Analytical Chemistry
  • Spectroscopy

Cite this

Görög, S., Babják, M., Balogh, G., Brlik, J., Csehi, A., Dravecz, F., ... Varga, K. (1997). Drug impurity profiling strategies. Talanta, 44(9), 1517-1526. https://doi.org/10.1016/S0039-9140(96)02179-0

Drug impurity profiling strategies. / Görög, S.; Babják, M.; Balogh, G.; Brlik, J.; Csehi, A.; Dravecz, F.; Gazdag, M.; Horváth, P.; Laukó, A.; Varga, K.

In: Talanta, Vol. 44, No. 9, 09.1997, p. 1517-1526.

Research output: Contribution to journalArticle

Görög, S, Babják, M, Balogh, G, Brlik, J, Csehi, A, Dravecz, F, Gazdag, M, Horváth, P, Laukó, A & Varga, K 1997, 'Drug impurity profiling strategies', Talanta, vol. 44, no. 9, pp. 1517-1526. https://doi.org/10.1016/S0039-9140(96)02179-0
Görög S, Babják M, Balogh G, Brlik J, Csehi A, Dravecz F et al. Drug impurity profiling strategies. Talanta. 1997 Sep;44(9):1517-1526. https://doi.org/10.1016/S0039-9140(96)02179-0
Görög, S. ; Babják, M. ; Balogh, G. ; Brlik, J. ; Csehi, A. ; Dravecz, F. ; Gazdag, M. ; Horváth, P. ; Laukó, A. ; Varga, K. / Drug impurity profiling strategies. In: Talanta. 1997 ; Vol. 44, No. 9. pp. 1517-1526.
@article{90ea08cf4dae4329b23933dd2e0ea318,
title = "Drug impurity profiling strategies",
abstract = "A general scheme is set up for the estimation of the impurity profile of bulk drug substances by the complex use of chromatographic, spectroscopic and hyphenated techniques. Several examples are presented as illustrations to the scheme from the authors laboratory involving the use of chromatographic methods such as thin-layer-(TLC), gas-(GC), analytical and preparative high-performance liquid chromatography (HPLC), spectroscopic methods such as mass spectrometry (MS) and NMR spectroscopy as well as hyphenated techniques (HPLC/diode-array UV, GC/MS and HPLC/MS). In addition to summarizing earlier work, new examples are also presented: identification of an impurity (propyl 4-[diethylcarbamoyl(methoxy)]-3-methoxy phenylglyoxylate, II) in propanidid (I) and two unsaturated impurities in allylestrenol (VII) by GC/MS and HPLC/diode-array UV as well as estimation of the impurity profile of mazipredone (III) by HPLC/MS and HPLC/diode-array UV.",
keywords = "Allylestrenol, Impurities, Mazipredone, Propanidid",
author = "S. G{\"o}r{\"o}g and M. Babj{\'a}k and G. Balogh and J. Brlik and A. Csehi and F. Dravecz and M. Gazdag and P. Horv{\'a}th and A. Lauk{\'o} and K. Varga",
year = "1997",
month = "9",
doi = "10.1016/S0039-9140(96)02179-0",
language = "English",
volume = "44",
pages = "1517--1526",
journal = "Talanta",
issn = "0039-9140",
publisher = "Elsevier",
number = "9",

}

TY - JOUR

T1 - Drug impurity profiling strategies

AU - Görög, S.

AU - Babják, M.

AU - Balogh, G.

AU - Brlik, J.

AU - Csehi, A.

AU - Dravecz, F.

AU - Gazdag, M.

AU - Horváth, P.

AU - Laukó, A.

AU - Varga, K.

PY - 1997/9

Y1 - 1997/9

N2 - A general scheme is set up for the estimation of the impurity profile of bulk drug substances by the complex use of chromatographic, spectroscopic and hyphenated techniques. Several examples are presented as illustrations to the scheme from the authors laboratory involving the use of chromatographic methods such as thin-layer-(TLC), gas-(GC), analytical and preparative high-performance liquid chromatography (HPLC), spectroscopic methods such as mass spectrometry (MS) and NMR spectroscopy as well as hyphenated techniques (HPLC/diode-array UV, GC/MS and HPLC/MS). In addition to summarizing earlier work, new examples are also presented: identification of an impurity (propyl 4-[diethylcarbamoyl(methoxy)]-3-methoxy phenylglyoxylate, II) in propanidid (I) and two unsaturated impurities in allylestrenol (VII) by GC/MS and HPLC/diode-array UV as well as estimation of the impurity profile of mazipredone (III) by HPLC/MS and HPLC/diode-array UV.

AB - A general scheme is set up for the estimation of the impurity profile of bulk drug substances by the complex use of chromatographic, spectroscopic and hyphenated techniques. Several examples are presented as illustrations to the scheme from the authors laboratory involving the use of chromatographic methods such as thin-layer-(TLC), gas-(GC), analytical and preparative high-performance liquid chromatography (HPLC), spectroscopic methods such as mass spectrometry (MS) and NMR spectroscopy as well as hyphenated techniques (HPLC/diode-array UV, GC/MS and HPLC/MS). In addition to summarizing earlier work, new examples are also presented: identification of an impurity (propyl 4-[diethylcarbamoyl(methoxy)]-3-methoxy phenylglyoxylate, II) in propanidid (I) and two unsaturated impurities in allylestrenol (VII) by GC/MS and HPLC/diode-array UV as well as estimation of the impurity profile of mazipredone (III) by HPLC/MS and HPLC/diode-array UV.

KW - Allylestrenol

KW - Impurities

KW - Mazipredone

KW - Propanidid

UR - http://www.scopus.com/inward/record.url?scp=0037900217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037900217&partnerID=8YFLogxK

U2 - 10.1016/S0039-9140(96)02179-0

DO - 10.1016/S0039-9140(96)02179-0

M3 - Article

VL - 44

SP - 1517

EP - 1526

JO - Talanta

JF - Talanta

SN - 0039-9140

IS - 9

ER -